Scholarlink

<p>Nanoparticles (NPs) have revolutionized medical diagnosis and treatment, offering innovative solutions and improved therapeutic outcomes. Particle size (PS) is a key factor determining the efficacy of nanomedical developments, influencing NPs’ internalization, targeting, and drug release. In our study, we modulated the size of four representative types of NPs: lipid, metallic, and polymeric (albumin and chitosan) NPs, by evaluating critical factors influencing particle formation. For metallic NPs, silver NPs were synthesized via chemical reduction with ascorbic acid, and a direct relationship was observed between pH in solution and PS (18.62 ± 4.12&#xa0;nm at pH 13, 67.89 ± 8.84&#xa0;nm at pH 11, and 145.4 ± 0.53&#xa0;nm at pH 10). Albumin NPs (BSANPs) were first synthesized by desolvation using cross-linking agents (1,1′-carbonyldiimidazole and N-hydroxysuccinimide) and then separated by differential centrifugation, producing monodisperse solutions of BSANPs (32.28 ± 2.63&#xa0;nm, 59.89 ± 5.44&#xa0;nm, and 121.03 ± 1.2&#xa0;nm). The size of chitosan NPs was modulated via chitosan solution ratio and tripolyphosphate quantity (26.69 ± 2.99&#xa0;nm, 55.78 ± 4.36&#xa0;nm, and 82.04 ± 12.73&#xa0;nm). Nanostructured lipid carriers were controlled via Tween 80 surfactant concentration (26.69 ± 0.17&#xa0;nm, 55.78 ± 0.23&#xa0;nm, and 82.04 ± 0.21&#xa0;nm). Characterization methods included dynamic light scattering, transmission electron microscopy, and zeta potential measurement, revealing desirable NPs’ properties. Our findings demonstrate effective strategies for optimizing NPs’ size, providing valuable insights into synthesis parameters and PS interplay.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Size control of metal, protein, carbohydrate, and lipid-based nanoparticles for nanomedicine over the range 20–100 nm through manipulation of synthesis parameters

  • 期刊论文

  • 发表日期：

    2026年3月18日

查看全文
  • Candido Gomez Lara,
  • Rocio G Casañas Pimentel,
  • Mónica R Jaime Fonseca

摘要

Nanoparticles (NPs) have revolutionized medical diagnosis and treatment, offering innovative solutions and improved therapeutic outcomes. Particle size (PS) is a key factor determining the efficacy of nanomedical developments, influencing NPs’ internalization, targeting, and drug release. In our study, we modulated the size of four representative types of NPs: lipid, metallic, and polymeric (albumin and chitosan) NPs, by evaluating critical factors influencing particle formation. For metallic NPs, silver NPs were synthesized via chemical reduction with ascorbic acid, and a direct relationship was observed between pH in solution and PS (18.62 ± 4.12 nm at pH 13, 67.89 ± 8.84 nm at pH 11, and 145.4 ± 0.53 nm at pH 10). Albumin NPs (BSANPs) were first synthesized by desolvation using cross-linking agents (1,1′-carbonyldiimidazole and N-hydroxysuccinimide) and then separated by differential centrifugation, producing monodisperse solutions of BSANPs (32.28 ± 2.63 nm, 59.89 ± 5.44 nm, and 121.03 ± 1.2 nm). The size of chitosan NPs was modulated via chitosan solution ratio and tripolyphosphate quantity (26.69 ± 2.99 nm, 55.78 ± 4.36 nm, and 82.04 ± 12.73 nm). Nanostructured lipid carriers were controlled via Tween 80 surfactant concentration (26.69 ± 0.17 nm, 55.78 ± 0.23 nm, and 82.04 ± 0.21 nm). Characterization methods included dynamic light scattering, transmission electron microscopy, and zeta potential measurement, revealing desirable NPs’ properties. Our findings demonstrate effective strategies for optimizing NPs’ size, providing valuable insights into synthesis parameters and PS interplay.